Loading clinical trials...
Loading clinical trials...
The treatment of older patients with acute myeloid leukemia that is secondary to previous myelodysplastic syndrome, myeloproliferative neoplasm, or prior cytotoxic exposure remains unsatisfactory. We ...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
University Hospital, Toulouse
NCT05564390 · Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, and more
NCT03050268 · Acute Leukemia, Adenomatous Polyposis, and more
NCT07320235 · Relapsed Acute Myeloid Leukemia
NCT06782542 · Acute Myeloid Leukemia, IDH1 Mutation
NCT06439199 · Acute Myeloid Leukemia, Myelodysplastic Syndromes, and more
University Hospital Bordeaux
Bordeaux
University Hospital Toulouse
Toulouse
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions